Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Athenex, Inc.
  6. News
  7. Summary
    ATNX   US04685N1037

ATHENEX, INC.

(ATNX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Athenex: Q1 Earnings Snapshot

05/06/2021 | 08:37am EDT

BUFFALO, N.Y. (AP) _ Athenex Inc. (ATNX) on Thursday reported a loss of $25.6 million in its first quarter.

On a per-share basis, the Buffalo, New York-based company said it had a loss of 27 cents.

The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 37 cents per share.

The biopharmaceutical company posted revenue of $41 million in the period, which also beat Street forecasts. Three analysts surveyed by Zacks expected $19.5 million.

The company's shares closed at $4.55. A year ago, they were trading at $9.45.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ATNX at https://www.zacks.com/ap/ATNX

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

All news about ATHENEX, INC.
06/07SHAREHOLDER ALERT : Robbins LLP is Investigating Athenex, Inc. (ATNX) for Shareh..
BU
06/04ATHENEX  : Data From Phase 1 Study Indicates Oral Docetaxel as Effective as IV A..
MT
06/04Athenex Presents Data on Oral Docetaxel and Oral Paclitaxel at ASCO2021 Virtu..
GL
05/21ATHENEX  : Receives Positive Opinion From European Medicines Agency on Klisyri t..
MT
05/21ATHENEX  : Klisyri Receives Positive Opinion From European Medicines Agency to T..
MT
05/21Athenex Announces Klisyri® (tirbanibulin) Receives Positive CHMP Opinion from..
GL
05/17ATHENEX  : Texas Children's Cancer Center, and the Center for Cell and Gene Ther..
AQ
05/07INSIDER TRENDS : Athenex Insider Reports Option Conversion in Face of 90-Day Sel..
MT
05/06ATHENEX  : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
05/06ATHENEX : Q1 Earnings Snapshot
AQ
More news
Financials (USD)
Sales 2021 124 M - -
Net income 2021 -144 M - -
Net Debt 2021 46,2 M - -
P/E ratio 2021 -3,41x
Yield 2021 -
Capitalization 440 M 440 M -
EV / Sales 2021 3,91x
EV / Sales 2022 3,10x
Nbr of Employees 599
Free-Float 68,6%
Chart ATHENEX, INC.
Duration : Period :
Athenex, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ATHENEX, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 8,25 $
Last Close Price 4,71 $
Spread / Highest target 176%
Spread / Average Target 75,2%
Spread / Lowest Target -4,46%
EPS Revisions
Managers and Directors
NameTitle
Yiu Nam Lau Chairman & Chief Executive Officer
Randoll Sze Chief Financial Officer
Rudolf Kwan Chief Medical Officer
Jeffrey M. Yordon COO & President-Athenex Pharmaceutical Division
Teresa Bair Secretary, SVP-Administration & General Counsel
Sector and Competitors
1st jan.Capitalization (M$)
ATHENEX, INC.-57.41%440
GILEAD SCIENCES, INC.15.60%83 541
WUXI APPTEC CO., LTD.24.70%63 775
REGENERON PHARMACEUTICALS10.59%55 705
BIONTECH SE177.34%51 304
VERTEX PHARMACEUTICALS-20.58%48 628